Detection of Neoehrlichia mikurensis in 11 persons who attribute their persistent health complaints to a tick-borne disease.

Background: Neoehrlichia mikurensis infections can cause symptomatic disease, particular among immunosuppressed persons. Long-lasting asymptomatic carriage of N. mikurensis may be common in endemic areas.

Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.

Objective: To study the age at onset of relapsing-remitting multiple sclerosis (RRMS) during the past century.

Methods: This is a population-based cohort study of persons diagnosed with RRMS in Hordaland, Møre, and Romsdal counties, Western Norway, from 1920 to 2022. Individual patient data were available and assessed from previously conducted prevalence and incidence studies in addition to hospital records up until October 31, 2022.

Cancer related mortality in multiple sclerosis. A population based cohort study.

Background: Cancer is a major cause of death, but how cancer influences mortality risk in Multiple Sclerosis (MS) is unclear.

Objectives: Determine all-cause mortality and mortality following a cancer diagnosis among MS patients compared with matched population controls.

Methods: Norwegian MS patients born 1930 - 1979 (n= 6950) followed-up 1953 - 2016, were matched with 37 922 controls.

Mortality and cause of death in multiple sclerosis in western Norway 1950-2021: a registry-based linkage study.

Background: Persons with multiple sclerosis (pwMS) have higher risk of mortality compared with the general population. Longitudinal studies are important for understanding the evolution of survival in pwMS.

Objective: Examine changes in mortality among pwMS during the past seven decades.

The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis.

Background And Objectives: The relationship between smoking, long-term brain atrophy, and clinical disability in patients with multiple sclerosis (MS) is unclear. Here, we assessed long-term effects of smoking by evaluating MRI and clinical outcome measures after 10 years in smoking and nonsmoking patients with relapsing-remitting MS (RRMS).

Methods: We included 85 treatment-naive patients with RRMS with recent inflammatory disease activity who participated in a 10-year follow-up visit after a multicenter clinical trial of 24 months.